Livongo Health said today it closed a $52.5 million growth round, with funds slated to support its diabetes management program, expansion into other chronic conditions and an international launch.
The Livongo diabetes management program combines lifestyle coaching with a connected glucose meter, designed to automatically upload readings and provide real-time insights. It’s aimed at self-insured employers, payers and healthcare providers.
The round was co-led by existing investor General Catalyst and Kinnevik, and joined by EDBI, American Investment Holdings and Microsoft Ventures, the Mountain View, Calif.-based company said. The round was also joined by all previous investors, Livongo said.
“Livongo is one of the fastest growing companies in our portfolio and we are happy to double down to help the team expand their market leadership. Additionally, we are excited to see Livongo expand their service to offer comprehensive support for their members’ chronic needs beyond diabetes,” General Catalyst managing director Hemant Taneja said in a prepared response.
Livongo said it is hopeful for an internatoin lauch of its products this year.
“Our team is focused on empowering our members to live healthier lives, not just manage their chronic conditions. That means we have to address all of their health issues in a comprehensive way. In addition to diabetes, we’re focused on extending our program to support other chronic conditions like hypertension and to continue to deliver an experience that our members love while improving clinical results and lowering costs. This new funding will accelerate our investments in R&D and expansion of our rules engine from 10,000 to more than 100,000 rules, allowing us to completely personalize the experience our members have,” Livongo CEO Glen Tullman said in prepared remarks.
Last April, Livongo said it raised nearly $45 million in a Series C round with plans to use to grow the footprint of its digital diabetes management program.